InSitu Biologics, Inc. will share the latest investigational work on its hydrogel-lipid-microparticle matrix at the upcoming 47th Annual Regional and Acute Pain Medicine Meeting of the American Society of Regional Anesthesia in April 2022.
The presentation entitled “Pharmacokinetic Profile of a New Prolonged Drug Delivery Matrix for Peripheral Nerve Block” was authored by the following InSitu Biologics team members: Bill Taylor, Chief Science Officer; Dr. Kelsey Pflepsen, Formulation Scientist; and Dr. Mark Ereth, Chief Medical Officer. This scientific report will highlight the Company’s work on multiple drug formulations within the hydrogel-lipid-microparticle matrix, demonstrating its ability to tune the matrix formulation’s drug-loading and prolonged-delivery characteristics. Refining the drug delivery formulation is one of the last steps needed to proceed to FDA submission for approval to advance to human trials.
“The presented results will highlight our team’s ability to tune the drug-delivery matrix to an optimally desired and clinically important duration of action,” said Dr. Mark Ereth, Chief Medical Officer of InSitu Biologics.
The abstract can be found here, and information on the ASRA meeting can be found here.
InSitu Biologics: InSitu Biologics is an emerging biotech company focused on the development of a multi-phase prolonged-release drug delivery platform for localized treatment of pain, cancer, and infection. The Company uses disruptive technology to address unmet needs in the pain management and drug delivery markets.
InSitu Biologics is currently conducting investigational pre-clinical work. The Company has no products approved for sale in any geography.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005019/en/
InSitu Biologics
Mark Ereth, MD
mark.ereth@insitubiologics.com
Source: InSitu Biologics, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20220331005019/en
